Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 1/20 | 0.38 |
| ▸ | CES2 | O00748 | 1/20 | 0.37 |
| ▸ | CES1 | P23141 | 1/20 | 0.37 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 3/20 | 0.35 |
| ▸ | MAPT | P10636 | 3/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.33 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | NPC1 | O15118 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | HPGD | P15428 | 2/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.32 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.32 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.32 |
| ▸ | RELA | Q04206 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL142885 | 0.85 | TAS1R3 (0.36) | ALOX5CES2CES1KEAP1RAB9A | |
| SCHEMBL141982 | 0.82 | HTT (0.40) | ALOX5CES2CES1KEAP1RAB9A | |
| SCHEMBL11169009 | 0.81 | HTT (0.36) | ALOX5CES2CES1KEAP1RAB9A | |
| SCHEMBL10652117 | 0.81 | CCR1 (0.39) | ALOX5CES2CES1KEAP1RAB9A | |
| SCHEMBL11314837 | 0.77 | FFAR1 (0.46) | ALOX5CES2CES1KEAP1RAB9A | |
| SCHEMBL7456996 | 0.75 | CTSC (0.38) | ALOX5CES2CES1KEAP1MAPT | |
| SCHEMBL7453262 | 0.74 | LMNA (0.35) | ALOX5CES2CES1KEAP1MAPT | |
| SCHEMBL919640 | 0.74 | — | — | |
| SCHEMBL144120 | 0.74 | — | — | |
| SCHEMBL23527680 | 0.73 | MIF (0.35) | ALOX5CES2CES1KEAP1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 524 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240084308-A1 | FIBROTIC TREATMENT | MONASH UNIVERSITY (AU) | 2024-03-14 | — | — | US | disclosed |
| US-20240034845-A1 | POLYMER PARTICLES | QUEENSLAND UNIVERSITY OF TECHNOLOGY (AU) | 2024-02-01 | — | — | US | disclosed |
| EP-3384549-B1 | SODIUM-ION ELECTROLYTE COMPOSITION | UNIV DEAKIN (AU) | 2024-01-17 | — | — | EP | disclosed |
| US-11834663-B2 | Fibrotic treatment | MONASH UNIVERSITY (AU) | 2023-12-05 | — | — | US | disclosed |
| US-20230348674-A1 | HYDROGELS | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) | 2023-11-02 | — | — | US | disclosed |
| WO-2023190111-A1 | RAFT POLYMERIZATION REACTION SOLUTION AND RAFT POLYMERIZATION REACTION SOLUTION PRODUCTION METHOD | テクノＵＭＧ株式会社 | 2023-10-05 | — | — | WO | disclosed |
| CN-113939544-B | non-core-shell polymer particles | 悉尼大学 | 2023-08-22 | — | — | CN | disclosed |
| CN-116615468-A | Polymer particles | 昆士兰科技大学 | 2023-08-18 | — | — | CN | disclosed |
| EP-4225811-A1 | POLYMER PARTICLES | Queensland University Of Technology (AU) | 2023-08-16 | — | — | EP | disclosed |
| WO-2023121483-A1 | IMMUNOSTIMULATORY COMPOSITIONS | VICTORIA LINK LIMITED (NZ) | 2023-06-29 | — | — | WO | disclosed |
| US-4981847-A | Tricyclic compounds | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1991-01-01 | — | — | US | disclosed |
| EP-0360079-A1 | Tricyclic compounds, processes for their preparation and pharmaceutical compositions comprising them | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1990-03-28 | — | — | EP | disclosed |
| EP-0336230-A2 | Cyclic peptide antagonists of Substance P and Substance K | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1989-10-11 | — | — | EP | disclosed |
| US-4497738-A | Analogous compounds of cephalosporins, processes for the preparation thereof and pharmaceutical composition comprising the same | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1985-02-05 | — | — | US | disclosed |
| US-4472300-A | ANTIMICROBIAL | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1984-09-18 | — | — | US | disclosed |
| EP-0017138-B1 | ANALOGOUS COMPOUNDS OF CEPHALOSPORINS, PROCESSES FOR THEIR PREPARATION, AND PHARMACEUTICAL COMPOSITION CONTAINING THEM | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1984-07-04 | — | — | EP | disclosed |
| EP-0070575-A2 | New starting compounds for preparing analogous compounds of cephalosporins and processes for their preparation | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1983-01-26 | — | — | EP | disclosed |
| US-4339449-A | Analogous compounds of cephalosporins, and pharmaceutical composition comprising the same | FUJISAWA PHARMACEUTICAL COMPANY, LIMITED (JP) | 1982-07-13 | — | — | US | disclosed |
| EP-0017138-A2 | Analogous compounds of cephalosporins, processes for their preparation, and pharmaceutical composition containing them | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1980-10-15 | — | — | EP | disclosed |
| US-4207234-A | 4-Unsubstituted azetidinone derivatives and process for preparation thereof | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1980-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11834663-B2 | Fibrotic treatment | MMP1, ENPEP, RNPEP | ALOX5 1983/4885CES2 957/4885CES1 436/4885 |
| US-20230348674-A1 | HYDROGELS | PHYKPL, TST, PHOSPHO1 | ALOX5 877/4885CES2 2684/4885CES1 3932/4885 |
| US-20240084308-A1 | FIBROTIC TREATMENT | MMP1, ENPEP, RNPEP | ALOX5 1983/4885CES2 957/4885CES1 436/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.